Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227551 · ClinicalTrials.gov registry record · Phase 2
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
A Phase 2 study, sponsored by Viralytics.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT01227551 is a Phase 2 study that has completed, run by Viralytics. The registered enrollment target is 57 participants.
The verdict
NCT01227551, a Phase 2 study, has completed, sponsored by Viralytics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria \[irRECIST 1.1\] (revised Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1).
Interventions
- BIOLOGICAL Coxsackievirus A21 (CVA21)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2011-12-29 |
| Est. Completion | 2016-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01227551
The ClinicalTrials.gov registry entry for NCT01227551 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viralytics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Coxsackievirus A21 (CVA21) is the first listed.
NCT01227551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01227551 about?
NCT01227551 is a clinical study titled "A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )". The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria \[irRECIST 1.1\] (revised Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1).
What is the current status of trial NCT01227551?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2011-12-29. Estimated completion is 2016-04-06.
What interventions are being tested in trial NCT01227551?
The interventions under investigation include: Coxsackievirus A21 (CVA21) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01227551?
This trial is sponsored by Viralytics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.